Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Roche persists; Ventana resists:

This article was originally published in Clinica

Executive Summary

Continuing its pursuit of Ventana Medical Systems, Roche has extended for the fourth time its offer for shares of the tissue-based diagnostics firm. The Swiss group is seeking to acquire Ventana for $75 per share - a proposal that the Tucson, Arizona company has steadfastly refused to accept - and has pushed the deadline for the tender offer to January 17 2008. So far, less than 0.2% of Ventana's 35 million outstanding shares have been tendered. Ventana's president and CEO Christopher Gleeson branded Roche's offer price as a -non-starter", as it did not reflect the company's full potential. The firm upped its revenue and earnings targets for 2007, after it saw its third-quarter sales jump 28% to reach $75.5m. Ventana attributed its top-line growth to its core advanced staining business gaining sales momentum and market share. The company now expects full-year revenue to be between $296-300m, and earnings to be around $1.34 per share.

Advertisement
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT050107

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel